These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 7599188)
1. Transcriptional down-regulation of c-myc expression in the MCF-7 breast tumor cell line by the topoisomerase II inhibitor, VM-26. Orr MS; Fornari FA; Randolph JK; Gewirtz DA Biochim Biophys Acta; 1995 Jun; 1262(2-3):139-45. PubMed ID: 7599188 [TBL] [Abstract][Full Text] [Related]
2. Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells. Magnet KJ; Orr MS; Cleveland JL; Rodriguez-Galindo C; Yang H; Yang C; Di YM; Jain PT; Gewirtz DA Biochem Pharmacol; 2001 Sep; 62(5):593-602. PubMed ID: 11585056 [TBL] [Abstract][Full Text] [Related]
3. Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line: evidence for induction of gene-specific damage and alterations in gene expression. Gewirtz DA; Orr MS; Fornari FA; Randolph JK; Yalowich JC; Ritke MK; Povirk LF; Bunch RT Cancer Res; 1993 Aug; 53(15):3547-54. PubMed ID: 8339261 [TBL] [Abstract][Full Text] [Related]
4. Estrogen-induced post-transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells. Santos GF; Scott GK; Lee WM; Liu E; Benz C J Biol Chem; 1988 Jul; 263(20):9565-8. PubMed ID: 3290209 [TBL] [Abstract][Full Text] [Related]
5. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26. Kim R; Beck WT Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863 [TBL] [Abstract][Full Text] [Related]
6. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Fornari FA; Jarvis DW; Grant S; Orr MS; Randolph JK; White FK; Gewirtz DA Biochem Pharmacol; 1996 Apr; 51(7):931-40. PubMed ID: 8651943 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional down-regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine. Clary A; Larrue A; Pourquier P; Robert J Anticancer Drugs; 1998 Mar; 9(3):245-54. PubMed ID: 9625435 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924 [TBL] [Abstract][Full Text] [Related]
9. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888 [TBL] [Abstract][Full Text] [Related]
10. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26. Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414 [TBL] [Abstract][Full Text] [Related]
11. Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells. Jain PT; Fornari FA; Randolph JK; Orr MS; Gewirtz DA Biochem Pharmacol; 1998 Apr; 55(8):1263-9. PubMed ID: 9719482 [TBL] [Abstract][Full Text] [Related]
12. Transcriptional down-regulation of c-myc expression by protein synthesis-dependent and -independent pathways in a human T lymphoblastic tumor cell line. Bading H; Moelling K Cell Growth Differ; 1990 Mar; 1(3):113-7. PubMed ID: 2127692 [TBL] [Abstract][Full Text] [Related]
13. Regulation of topoisomerase II expression during the VM-26 induced differentiation of IW32 murine erythroleukemia cells. Tan SK; Tang SJ; Wang MC; Hwang J; Wang FF Leuk Res; 1996 Mar; 20(3):249-57. PubMed ID: 8637220 [TBL] [Abstract][Full Text] [Related]
14. Myc protein is differentially sensitive to quinidine in tumor versus immortalized breast epithelial cell lines. Melkoumian ZK; Martirosyan AR; Strobl JS Int J Cancer; 2002 Nov; 102(1):60-9. PubMed ID: 12353235 [TBL] [Abstract][Full Text] [Related]
15. Estradiol stimulates c-myc proto-oncogene expression in normal human breast epithelial cells in culture. Leygue E; Gol-Winkler R; Gompel A; Louis-Sylvestre C; Soquet L; Staub S; Kuttenn F; Mauvais-Jarvis P J Steroid Biochem Mol Biol; 1995 Apr; 52(4):299-305. PubMed ID: 7734397 [TBL] [Abstract][Full Text] [Related]
16. Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells. Bunch RT; Povirk LF; Orr MS; Randolph JK; Fornari FA; Gewirtz DA Biochem Pharmacol; 1994 Jan; 47(2):317-29. PubMed ID: 8304976 [TBL] [Abstract][Full Text] [Related]
17. c-fos is a positive regulator of carcinogen enhancement of adenovirus transformation. Su ZZ; Yemul S; Stein CA; Fisher PB Oncogene; 1995 May; 10(10):2037-49. PubMed ID: 7761104 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of topoisomerase II does not inhibit transcription of RNA polymerase I and II genes. Dunaway M Mol Cell Biol; 1990 Jun; 10(6):2893-900. PubMed ID: 2160588 [TBL] [Abstract][Full Text] [Related]
19. Changes in c-myc and c-fos expression in a human tumor cell line following exposure to bifunctional alkylating agents. Futscher BW; Erickson LC Cancer Res; 1990 Jan; 50(1):62-6. PubMed ID: 2104539 [TBL] [Abstract][Full Text] [Related]